ZDLD20
ZDLD20, a β-carboline, is orally active and selective CDK4/CycD3 inhibitor with an IC50 value of 6.51 μM. ZDLD20 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD20 exhibits potent anticancer activity[1].
Product Specifications
CAS Number
2762279-02-5
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/zdld20.html
Purity
99.84
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=NC=CC2=C1NC3=C2C=CC=C3)NC4=NC=C(N5CCN(C)CC5)C=C4
Molecular Formula
C22H22N6O
Molecular Weight
386.45
References & Citations
[1]Deping Li, et al. Facile synthesis of C1-substituted β-carbolines as CDK4 inhibitors for the treatment of cancer. Bioorg Chem. 2022 Apr;121:105659.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Aquaporin 9 (AQP9) Human shRNA Plasmid Kit (Locus ID 366)
MLH1 (Human Mul L Homologue, Familial Nonpolyposis Colin Cancer Type 2, COCA2, Colon Cancer Type 2, COCA2, FCC2, HNPCC, HNPCC2, MGC5172, hMLH1) (MaxLight 550)
MLH1 (Human Mul L Homologue, Familial Nonpolyposis Colin Cancer Type 2, COCA2, Colon Cancer Type 2, COCA2, FCC2, HNPCC, HNPCC2, MGC5172, hMLH1) (MaxLight 550)
FZD2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
